Graft Versus Host Disease (GvHD) Treatment Market
Demand for Corticosteroid-based (GvHD) Treatment to experience noteworthy incline
Graft Versus Host Disease (GvHD) Treatment Market by Product, Disease & Region - Forecast 2022 - 2032
Graft Versus Host Disease (GvHD) Treatment Market Outlook (2022-2032)
[311 Pages Report] The global graft versus host disease (GvHD) treatment market is expected to secure US$ 5,655.37 Million in 2032 while expanding at a CAGR of 8.3%.
The market is experiencing a steady growth in corticosteroids and combination therapies for graft-versus-host disease in HCT patients boosting the market for (GvHD) treatment. The market is likely to hold a value of US$ 2,547.86 Million in 2022. From 2016-21, the market displayed a growth rate of 7.8%.
Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival and acute graft-versus-host disease ((GVHD)) severity levels, however, there are a number of challenges that must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications.
|
Data Points |
Key Statistics |
|
Projected Market Value (2022) |
US$ 2,547.86 Million |
|
Anticipated Forecast Value (2032) |
US$ 5,655.376 Million |
|
Estimated Growth Rate (2022-2032) |
8.3% CAGR |
For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the U.S. Food and Drug Administration in December 2021. In addition to treating autoimmune disorders, Orencia is also used to prevent them. T-cells are a key component of acute (GVHD), and this drug circumvents their attack by specifically binding to and modulating one of the main costimulation signals sent by these cells.
This prevents a full activation of T-cells, which prevents acute (GVHD) from occurring. A number of new approaches are being evaluated by doctors in order to prevent (GVHD) in the future.
Further, approval of Orencia will make stem cell transplants more accessible to a larger number of cancer patients and people with blood disorders, particularly people from diverse ethnic backgrounds. To improve treatment response, future treatments may include immunosuppression and other treatment agents, such as regenerative or tissue-repairing agents to the market.
Let us know your requirement to get
100% FREE customization
Factors Contributing To The Growth Of The Global Graft Versus Host Disease (Gvhd) Treatment Market?
A healthy CAGR is expected to be observed for graft versus host disease treatment during the forecast period. As innovative technologies are developed, and cancer patients seek out chemotherapy treatments, the graft versus host disease ((GvHD)) treatment market is expected to grow from 2022-2032.
Cancer patients who are treated with chemotherapy are the main driving force behind the graft versus host disease ((GvHD)) market at present. Increasing bone marrow transplants to treat specific cancers is also fueling the global graft versus host disease market.
Human health products have become increasingly innovative and effective in recent decades. Growth in graft versus host disease ((GvHD)) will be considerably impacted by the use of allogeneic stem cell transplants.
In order to stay competitive, key players focus on introducing new drugs to the market. As a result of the high investments made by the public and private sectors in R&D technology and infrastructure, it is expected that the market will be provided with lucrative opportunities in the near future.
A global economy that focuses on advancing technology and innovation has the potential to restore growth and ensure the future competitiveness of the pharmaceutical industry by investing in innovation and research.
What Factors are impeding the Global Market for Graft Versus Host Disease (GvHD) Treatments?
Global graft versus host disease ((GvHD)) market growth is likely to be hindered by costs associated with recent clinical trials and authorizations. Using steroids in the treatment of (GvHD) immune diseases, skin diseases, and other conditions may result in side effects such as glucose levels increasing, fluid retention, mood problems, appetite disorders, and stomach pain.
The use of steroids over a long period of time has been linked to diabetes, infection, muscle weakness, and even cancer.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhy Is The Global Market For Graft Versus Host Disease (Gvhd) Treatments Expected To Dominate North America?
As per the analysis, the global graft versus host disease (GvHD) treatment market is expected to be dominated by North America during the forecast period. In 2022, the region is expected to secure about 34% of the total market share. As a result of a well-established medical infrastructure and the proliferation of major key players in the region, the region has become a dominant market for (GvHD) treatments.
The United States is expected to contribute the most to the development of the market during the forecast period. Growing awareness of (GVHD) has boosted the market for (GvHD) treatments in this region. New medicines are expected to propel the market growth during the forecast period. Additionally, the regulatory authority's approval for various medicines in the market also contributes to the growth of the region.
For instance, on September 22, 2021, the FDA approved Ruxolitinib for chronic graft-versus-host disease ((GVHD)) in adults and children over 12 years of age who have failed one or more lines of systemic therapy. REACH-3 (NCT03112603) evaluated ruxolitinib's efficacy as a treatment for corticosteroid-refractory chronic (GVHD) after allogeneic stem cell transplantation compared with the best available therapy (BAT) on the market.
How Has Europe Contributed To The Growth Of The Global Graft Versus Host Disease Treatment Market?
According to the analysis, Europe is projected to be the second-largest market during the forecast period. It is estimated that the region will hold 21% of the total market share in 2022. The growth of the market can be attributed to the rapid development of the food and beverage sector in the region.
Growing awareness, the availability of chemotherapies, and the adoption of advanced cancer treatment technologies drive the market for graft versus host disease ((GvHD)) treatment in these regions. In addition, rise in the aging population, scientific advancements, and clinical trials are expected to grow the market for GvHD treatment in the market.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
What are the Most Effective Products on the Market for Treating GvHD?
According to Future Market Insights, monoclonal antibodies are expected to gain significant market share in the upcoming years. With the rapid development of pharmaceuticals and clinical trials, along with the expanding treatment for chronic diseases, the worldwide market is set for continued expansion in the near future.
The increasing number of cancer cases in various regions has fuelled the growth of this market in recent years. Due to their specialization in targeted cancer therapies in the medical sector, monoclonal antibodies are in high demand due to their unique properties.
Furthermore, some monoclonal antibodies are also immunotherapies since they are effective in fighting cancer by turning the immune system against the disease. These treatment types are therefore growing in the market.
How likely is it that the market for Acute Graft Versus Host Disease (GvHD) will grow in the future?
The use of various treatments for GvHD is expected to drive the market and account for the greatest share in 2022. Globally, the market is expected to grow at a significant CAGR, attracting private and public investments to this market.
Ruxolitinib is becoming more widely used as an alternative treatment option for acute graft versus host disease ((GvHD)), which reduces the need for hospitalization unless there are complications. Increasing immunosuppression is often successfully achieved through the administration of oral or intravenous steroid medications.
The severe complications of acute graft-versus-host disease ((GVHD)) continue to hinder the success of allogeneic hematopoietic stem cell transplants (HSCTs). As a treatment when prophylaxis fails or remains suboptimal, the ability to prevent (GVHD) prophylaxis is crucial. The most commonly prescribed regimen for prophylaxis of (GVHD) still consists of a calcineurin inhibitor in combination with methotrexate.
How are Start-Up Companies Playing a Role in Augmenting Sales of Graft Versus Host Disease (GvHD) Treatment?
Healthcare continues to be a flourishing sector, and the demand for safe and effective medications is on the rise. Numerous innovative medicine solutions have been introduced in the medical field to reduce side effects and improve long-term outcomes, including the incorporation of graft versus host disease (GvHD) treatment. As start-ups realize its potential, they are firmly establishing themselves on the global market.
Some notable graft versus host disease start-up manufacturers are as follows:
- Astellas Pharma, founded in 2005 as a Japanese multinational pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. A number of drugs have been developed by the company that are used effectively to treat (GVHD) diseases and other chronic diseases.
- Mesoblast Ltd, a U.K-based graft versus host disease (GvHD) treatment manufacturer, offers allogeneic cellular medicines are being developed and commercialized by Mesoblast using its proprietary technology platform to treat diseases that are resistant to conventional treatments and in which inflammation is a significant factor. Among the Company's Phase 3 products are remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-a(GVHD)), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for severe chronic heart failure; and MPC-06-ID for degenerative disc disease-related chronic low back pain.
- Equillium, Inc. develops unmet medical needs in the treatment of severe autoimmune and inflammatory disorders by leveraging a deep understanding of immunobiology. The company is situated in California, United States and was foun in 2017. A Phase 3 study is currently underway for graft-versus-host disease patients and a Phase 1b trial has been initiated for patients with lupus/lupus nephritis patients. An alopecia areata study is expected to begin enrolling patients in the second half of 2022 with EQ101, a first-in-class tri-specific cytokine inhibitor that targets IL-2, IL-9, and IL-15.
Competition Analysis
Key players in the global graft versus host disease (GvHD) treatment market include Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH,Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others.
- In March 2022, Equillium, Inc. announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (GvHD)). As first-line therapy for (GvHD) combined with corticosteroids, itolizumab will be compared with placebo in a randomized, double-blind study.
- In May 2022, Novartis announced the approval of European Commission (EC) for Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic (GvHD) who have suffered from an insufficient response to corticosteroids or other systemic treatments. A new way to manage (GvHD) that is debilitating and life-threatening is now possible with Jakavi, which qualifies as a new option for healthcare providers and patients.
Report Scope
|
Growth Rate (2022-2032) |
8.3% CAGR |
|
Market Value in 2022 |
US$ 2,547.86 Million |
|
Market Value in 2032 |
US$ 5,655.37 Million |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
USD Million for Value |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization Scope |
Available upon Request |
Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market
Graft Versus Host Disease (GvHD) Treatment Market by Product:
- Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment
- mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment
- Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment
- Thalidomide Graft Versus Host Disease (GvHD) Treatment
- Etanercept Graft Versus Host Disease (GvHD) Treatment
Graft Versus Host Disease (GvHD) Treatment Market by Disease:
- Acute Graft Versus Host Disease (a(GvHD))
- Chronic Graft Versus Host Disease (c(GvHD))
Graft Versus Host Disease (GvHD) Treatment Market by Region:
- North America Graft Versus Host Disease (GvHD) Treatment Market
- Latin America Graft Versus Host Disease (GvHD) Treatment Market
- Europe Graft Versus Host Disease (GvHD) Treatment Market
- Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market
- Middle East & Africa Graft Versus Host Disease (GvHD) Treatment Market
Frequently Asked Questions
FMI projects the global graft versus host disease (GvHD) treatment market to expand at an 8.3% value CAGR by 2032
North America is expected to be the most opportunistic graft versus host disease (GvHD) treatment market, accumulating 34% revenue in 2022
Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others. Are among the prominent companies recognized globally in graft versus host disease (GvHD) treatment.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2016-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Disease
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Disease, 2016-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease, 2022-2032
5.3.1. Acute graft versus host disease (aGvHD)
5.3.2. Chronic graft versus host disease (cGvHD)
5.4. Y-o-Y Growth Trend Analysis By Disease, 2016-2021
5.5. Absolute $ Opportunity Analysis By Disease, 2022-2032
6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Product
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Product, 2016-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product, 2022-2032
6.3.1. mTOR inhibitors Graft Versus Host Disease GvHD Treatment
6.3.2. Tyrosine kinase inhibitors Graft Versus Host Disease GvHD Treatment
6.3.3. Monoclonal antibodies Graft Versus Host Disease GvHD Treatment
6.3.4. Etanercept Graft Versus Host Disease GvHD Treatment
6.3.5. Thalidomide Graft Versus Host Disease GvHD Treatment
6.3.6. Others Graft Versus Host Disease GvHD Treatment
6.4. Y-o-Y Growth Trend Analysis By Product, 2016-2021
6.5. Absolute $ Opportunity Analysis By Product, 2022-2032
7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Disease
8.2.3. By Product
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Disease
8.3.3. By Product
8.4. Key Takeaways
9. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Disease
9.2.3. By Product
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease
9.3.3. By Product
9.4. Key Takeaways
10. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Disease
10.2.3. By Product
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease
10.3.3. By Product
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Malaysia
11.2.1.5. Singapore
11.2.1.6. Australia
11.2.1.7. Rest of Asia Pacific
11.2.2. By Disease
11.2.3. By Product
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease
11.3.3. By Product
11.4. Key Takeaways
12. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Disease
12.2.3. By Product
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease
12.3.3. By Product
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. U.K.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Disease
13.1.2.2. By Product
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Disease
13.2.2.2. By Product
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Disease
13.3.2.2. By Product
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Disease
13.4.2.2. By Product
13.5. Rest of Latin America
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Disease
13.5.2.2. By Product
13.6. Germany
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Disease
13.6.2.2. By Product
13.7. U.K.
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Disease
13.7.2.2. By Product
13.8. France
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Disease
13.8.2.2. By Product
13.9. Spain
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Disease
13.9.2.2. By Product
13.10. Italy
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Disease
13.10.2.2. By Product
13.11. Rest of Europe
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Disease
13.11.2.2. By Product
13.12. China
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Disease
13.12.2.2. By Product
13.13. Japan
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Disease
13.13.2.2. By Product
13.14. South Korea
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Disease
13.14.2.2. By Product
13.15. Malaysia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Disease
13.15.2.2. By Product
13.16. Singapore
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Disease
13.16.2.2. By Product
13.17. Australia
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Disease
13.17.2.2. By Product
13.18. Rest of Asia Pacific
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Disease
13.18.2.2. By Product
13.19. GCC Countries
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Disease
13.19.2.2. By Product
13.20. South Africa
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2021
13.20.2.1. By Disease
13.20.2.2. By Product
13.21. Israel
13.21.1. Pricing Analysis
13.21.2. Market Share Analysis, 2021
13.21.2.1. By Disease
13.21.2.2. By Product
13.22. Rest of MEA
13.22.1. Pricing Analysis
13.22.2. Market Share Analysis, 2021
13.22.2.1. By Disease
13.22.2.2. By Product
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Disease
14.3.3. By Product
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Novartis AG
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Merck & Co.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Neovii Biotech GmbH
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Astellas Pharma Inc.
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Soligenix
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Mesoblast Ltd
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Pfizer
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Sanofi
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Takeda Pharmaceutical
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Abbott
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Forecast by Region, 2016-2032
Table 02: Global Market Value (US$ Mn) Forecast by Disease, 2016-2032
Table 03: Global Market Value (US$ Mn) Forecast by Product, 2016-2032
Table 04: North America Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 05: North America Market Value (US$ Mn) Forecast by Disease, 2016-2032
Table 06: North America Market Value (US$ Mn) Forecast by Product, 2016-2032
Table 07: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 08: Latin America Market Value (US$ Mn) Forecast by Disease, 2016-2032
Table 09: Latin America Market Value (US$ Mn) Forecast by Product, 2016-2032
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 11: Europe Market Value (US$ Mn) Forecast by Disease, 2016-2032
Table 12: Europe Market Value (US$ Mn) Forecast by Product, 2016-2032
Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Disease, 2016-2032
Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Product, 2016-2032
Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 17: MEA Market Value (US$ Mn) Forecast by Disease, 2016-2032
Table 18: MEA Market Value (US$ Mn) Forecast by Product, 2016-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Mn) by Disease, 2022-2032
Figure 02: Global Market Value (US$ Mn) by Product, 2022-2032
Figure 03: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 04: Global Market Value (US$ Mn) Analysis by Region, 2016-2032
Figure 05: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 06: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 07: Global Market Value (US$ Mn) Analysis by Disease, 2016-2032
Figure 08: Global Market Value Share (%) and BPS Analysis by Disease, 2022-2032
Figure 09: Global Market Y-o-Y Growth (%) Projections by Disease, 2022-2032
Figure 10: Global Market Value (US$ Mn) Analysis by Product, 2016-2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Product, 2022-2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Product, 2022-2032
Figure 13: Global Market Attractiveness by Disease, 2022-2032
Figure 14: Global Market Attractiveness by Product, 2022-2032
Figure 15: Global Market Attractiveness by Region, 2022-2032
Figure 16: North America Market Value (US$ Mn) by Disease, 2022-2032
Figure 17: North America Market Value (US$ Mn) by Product, 2022-2032
Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Market Value (US$ Mn) Analysis by Disease, 2016-2032
Figure 23: North America Market Value Share (%) and BPS Analysis by Disease, 2022-2032
Figure 24: North America Market Y-o-Y Growth (%) Projections by Disease, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Product, 2016-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Product, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Product, 2022-2032
Figure 28: North America Market Attractiveness by Disease, 2022-2032
Figure 29: North America Market Attractiveness by Product, 2022-2032
Figure 30: North America Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Market Value (US$ Mn) by Disease, 2022-2032
Figure 32: Latin America Market Value (US$ Mn) by Product, 2022-2032
Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Market Value (US$ Mn) Analysis by Disease, 2016-2032
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Disease, 2022-2032
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Disease, 2022-2032
Figure 40: Latin America Market Value (US$ Mn) Analysis by Product, 2016-2032
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Product, 2022-2032
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Product, 2022-2032
Figure 43: Latin America Market Attractiveness by Disease, 2022-2032
Figure 44: Latin America Market Attractiveness by Product, 2022-2032
Figure 45: Latin America Market Attractiveness by Country, 2022-2032
Figure 46: Europe Market Value (US$ Mn) by Disease, 2022-2032
Figure 47: Europe Market Value (US$ Mn) by Product, 2022-2032
Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Market Value (US$ Mn) Analysis by Disease, 2016-2032
Figure 53: Europe Market Value Share (%) and BPS Analysis by Disease, 2022-2032
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Disease, 2022-2032
Figure 55: Europe Market Value (US$ Mn) Analysis by Product, 2016-2032
Figure 56: Europe Market Value Share (%) and BPS Analysis by Product, 2022-2032
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Product, 2022-2032
Figure 58: Europe Market Attractiveness by Disease, 2022-2032
Figure 59: Europe Market Attractiveness by Product, 2022-2032
Figure 60: Europe Market Attractiveness by Country, 2022-2032
Figure 61: Asia Pacific Market Value (US$ Mn) by Disease, 2022-2032
Figure 62: Asia Pacific Market Value (US$ Mn) by Product, 2022-2032
Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Disease, 2016-2032
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Disease, 2022-2032
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease, 2022-2032
Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Product, 2016-2032
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2022-2032
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2022-2032
Figure 73: Asia Pacific Market Attractiveness by Disease, 2022-2032
Figure 74: Asia Pacific Market Attractiveness by Product, 2022-2032
Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 76: MEA Market Value (US$ Mn) by Disease, 2022-2032
Figure 77: MEA Market Value (US$ Mn) by Product, 2022-2032
Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: MEA Market Value (US$ Mn) Analysis by Disease, 2016-2032
Figure 83: MEA Market Value Share (%) and BPS Analysis by Disease, 2022-2032
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Disease, 2022-2032
Figure 85: MEA Market Value (US$ Mn) Analysis by Product, 2016-2032
Figure 86: MEA Market Value Share (%) and BPS Analysis by Product, 2022-2032
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Product, 2022-2032
Figure 88: MEA Market Attractiveness by Disease, 2022-2032
Figure 89: MEA Market Attractiveness by Product, 2022-2032
Figure 90: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
